Types and Severity of Hearing Loss among Patients with Tuberculosis receiving Anti-Tuberculosis Treatment in Nigeria: A Single Center Study.
Main Article Content
Keywords
Tuberculosis, Anti-tuberculosis drugs, Hearing loss, Types, Severity, Nigeria
Abstract
Background: Tuberculosis (TB) is a contagious and potentially fatal infectious disease with significant global morbidity and mortality. Boththe disease and some anti-TB medications have been linked to hearing loss. The study objective is to determine the Types and severity of hearing loss among patients receiving anti-tuberculosis drugs at NAUTH, Nnewi, Nigeria.
Methodology: This prospective cohort study, conducted over one year at Nnamdi Azikiwe University Teaching Hospital (NAUTH) among adults enrolled in TB patients 18-60years and healthy controlsusing convenient sampling .GeneXpert/AFB testing was used for TB diagnosis,and pure tone audiometrywas done for all participants,with follow-up assessments at 2 and 3 months for TB patients. Statistical analysis was performed using STATA version 16.0, with significance set at p < 0.05.
Results: A total of 196 participants, which included 98 Tb cases(80 drug sensitive TB(DSTB),18multi drug resistant TB(MDRTB), and 98 controls, with a male:femaleratio of1.13:1,mean age 33.82 ± 12.22 years, with an age range of 18-60 years, were recruited.After 90 days of anti-TB treatment, 4.1% of participants developed sensorineural hearing loss, with 3 cases classified as moderate seen among the MDRTB group and 1 case as mild among the DSTB group. There was no significant difference in mean pure tone hearing thresholds between the treatment and control groups in both ears (p = 0.395).
Conclusion: Incidence of Bilateral demonstrable hearing loss after anti-TB drugs,which is common among MDRTB,has dropped with the introduction of all oral shorter regimens.
References
2. Adamu AL, Gadanya MA, Abubakar IS, Jibo AM, Bello MM, Gajida AU, et al. High mortality among tuberculosis patients on treatment in Nigeria: a retrospective cohort study. BMC Infect Dis. 2017 Dec;17(1):170.
3. Golden MP, Vikram HR. Extrapulmonary Tuberculosis: An Overview.
4. Abes GT, Abes LLB, Jamir C. The Variable Clinical Presentation of Tuberculosis Otitis Media and the Importance of Early Detection. 2011;32(4).
5. Tang IP, Prepageran N, Ong CA, Puraviappan P. Diagnostic challenges in tuberculous otitis media. J Laryngol Otol. 2010 Aug;124(8):913–5.
6. Skolnik PR, Nadol JB, Baker AS. Tuberculosis of the Middle Ear: Review of the Literature with an Instructive Case Report. Clinical Infectious Diseases. 1986 May 1;8(3):403–10.
7. Weiner GM, O’Connell JE, Pahor AL. The role of surgery in tuberculous mastoiditis: appropriate chemotherapy is not always enough. J Laryngol Otol. 1997 Aug;111(8):752–3.
8. Mondal SK, Alam MM. Tuberculous otitis media. Mymensingh Med J. 2011 Apr;20(2):343–8.
9. Selimoglu E. Aminoglycoside-Induced Ototoxicity. CPD. 2007 Jan 1;13(1):119–26.
10. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012 Nov;40(5):1277–86.
11. Bardien S, Harris T, Schaaf H, Petersen L. Aminoglycoside-induced hearing loss : South Africans at risk. SAMJ. 2009;99(6):440–1.
12. Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB, White K, et al. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clinical Infectious Diseases. 2021 Nov 2;73(9):e3563–71.
13. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011 Sep;38(3):516–28.
14. Fisher LD. Self-designing clinical trials. Statist Med. 1998 Jul 30;17(14):1551–62.
15. Araoye M. Sample Size Determination. Research methoology with statistics for health and social sciences Ilorin: Nathadex Publishers. 2004;2004:115–8.
16. Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx. 2017 Aug;44(4):404–10.
17. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology. J Clin Microbiol. 2010 Jan;48(1):229–37.
18. Okonkwo R, Onwunzo M, Chukwuka C, Ele P, Anyabolu A, Onwurah C, et al. The Use of the Gene Xpert Mycobacterium tuberculosis/Rifampicin (MTB/Rif) Assay in Detection of Multi-Drug Resistant Tuberculosis (MDRTB) in Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. J HIV Retrovirus. 2017;03(01):1–5.
19. Yusuf NW. Rapid diagnosis of tuberculosis using Xpert MTB/RIF assay - Report from a third world country. Pak J Med Sci [Internet]. 2014 Nov 24 [cited 2025 Aug 15];31(1). Available from: http://pjms.com.pk/index.php/pjms/article/view/6970
20. Kim SC, Kang SI, Kim DW, Kim SC, Cho SN, Hwang JH, et al. Development and evaluation of an automated stainer for acid-fast bacilli. Medical Engineering & Physics. 2003 May;25(4):341–7.
21. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. The Lancet Infectious Diseases. 2006 Oct;6(10):664–74.
22. Hinchcliffe R. Recommended procedure for Rinne and Weber tuning fork tests. Br J Audiol. 1988 May;22(2):153.
23. Laura BS. Pure Tone Air Conduction and Bone Conduction Threshold Audiometry with and without Masking: Recommended Procedure. British Society of Audiology. 2017;1–37.
24. Olusanya BO, Newton VE. Global burden of childhood hearing impairment and disease control priorities for developing countries. The Lancet. 2007 Apr;369(9569):1314–7.
25. Roth TN, Hanebuth D, Probst R. Prevalence of age-related hearing loss in Europe: a review. Eur Arch Otorhinolaryngol. 2011 Aug;268(8):1101–7.
26. Lee PYC, Drysdale AJ. Tuberculous otitis media: a difficult diagnosis. J Laryngol Otol. 1993 Apr;107(4):339–41.
27. Huth ME, Ricci AJ, Cheng AG. Mechanisms of Aminoglycoside Ototoxicity and Targets of Hair Cell Protection. International Journal of Otolaryngology. 2011;2011:1–19.
28. Ibekwe M, Nwosu C. Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Med J. 2016;10(3):97.
29. Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification of functioning, disability and health. Bull World Health Organ. 2019 Oct 1;97(10):725–8.
30. Lory GL. STATA: Software for Statistics and Data Software. In: Barnes JC, Forde DR, editors. The Encyclopedia of Research Methods in Criminology and Criminal Justice [Internet]. 1st ed. Wiley; 2021 [cited 2025 Aug 15]. p. 875–9. Available from: https://onlinelibrary.wiley.com/doi/10.1002/9781119111931.ch170
31. Shrestha B, Dunn L. The Declaration of Helsinki on Medical Research involving Human Subjects: A Review of Seventh Revision. J Nepal Health Res Counc. 2020 Jan 21;17(4):548–52.
32. Sani R, Oyeleke S, Abalaka M, Garba S. Prevalence of Pulmonary Tuberculosis (PTB) in Minna and Suleja Niger State, Nigeria. American Journal of Medicine and Medical Sciences. 2015;5(6):287–91.
33. Imam T, Oyeyi T. A retrospective study of Pulmonary Tuberculosis (PTB) prevalence amongst patients attending infrectious diseases hospital, in Kano, Nigeria. Bayero J Pure App Sci. 2010 Aug 4;1(1):10–5.
34. Jiamsakul A, Lee MP, Nguyen KV, Merati TP, Cuong DD, Ditangco R, et al. Socio-economic status and risk of tuberculosis: a case-control study of HIV-infected patients in Asia. int j tuberc lung dis. 2018 Feb 1;22(2):179–86.
35. Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HGM, Mantel-Teeuwisse AK. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol. 2015 Dec;16(1):36.
36. Nizamuddin S, Khan F, Khan A, Kamaal C. Assessment of hearing loss in multi-drug resistant tuberculosis (MDR-TB) patients undergoing Aminoglycoside treatment. Int J Res Med Sci. 2015;1734–40.
37. Sharma V, Bhagat S, Verma B, Singh R, Singh S. Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis. Iranian Journal of Otorhinolaryngology. 2016;28(3):203–8.
38. Tiwari DM, Roy DAK, Shamaliya DK, Yadav DSK. Ototoxicity Associated With The Usage Of Injectable Kanamycin In Multi-Drug Resistant Tuberculosis Patientsduring Intensive Phase Of Category IV Treatment On DOTS-Plus Therapy. Journal of Dental and Medical Sciences. 2016;15(2):12–6.
39. Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, et al. Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014 Dec;14(1):542.
40. Sha SH, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hearing Research. 2001 May;155(1–2):1–8.
41. Karasawa T, Steyger PS. Intracellular mechanisms of aminoglycoside-induced cytotoxicity. Integr Biol. 2011;3(9):879.
42. Tabuchi K, Nishimura B, Nakamagoe M, Hayashi K, Nakayama M, Hara A. Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention. CMC. 2011 Nov 1;18(31):4866–71.
43. Cho Y, Lee H, Kim S, Chung K, Lee D, Koh W, et al. Tuberculous Otitis Media: A Clinical and Radiologic Analysis of 52 Patients. The Laryngoscope. 2006 Jun;116(6):921–7.
44. Barlow DW, Duckert LG, Kreig CS, Gates GA. Ototoxicity of Topical Otomicrobial Agents. Acta Oto-Laryngologica. 1995 Jan;115(2):231–5.
45. Haryuna TSH, Farhat F, Indriany S. Decreased Protein Kinase C Expression in the Cochlear Fibroblasts of Diabetic Rat Models Induced by Curcumin. tjps. 2019 Jun 1;16(2):169–74.
46. Kakigi A, Hirakawa H, Harel N, Mount RJ, Harrison RV. Basal Cochlear Lesions Result in Increased Amplitude of Otoacoustic Emissions. Audiol Neurotol. 1998;3(6):361–72.
47. Daniel SJ, Duval M, Sahmkow S, Akache F. Ototoxicity of Topical Moxifloxacin in a Chinchilla Animal Model. The Laryngoscope. 2007 Dec;117(12):2201–5.
48. Khoza-Shangase K, Prodromos M. Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin. South African Journal of Communication Disorders [Internet]. 2021 Jan 26 [cited 2025 Aug 15];68(1). Available from: http://www.sajcd.org.za/index.php/SAJCD/article/view/784
49. Sturdy A, Goodman A, Jose RJ, Loyse A, O’Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy. 2011 Aug 1;66(8):1815–20.
50. Mwansasu C, Siziya S, Mpondo B, Mwansasu CS. Hearing Loss among Multi-Drug Resistant Tuberculosis patients on Kanamycin in Ndola Teaching Hospital, Zambia: Study of ototoxicity and practice. Health Press Zambia Bull. 2017;1(4):72–8.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.